RVRémi Vergara

Rémi Vergara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rémi Vergara has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Rullier

    Laboratoire d'anatomie et cytologie pathologiques, CHU de Bordeaux, Bordeaux, France

    3 shared publications
  • Ivan Théate

    Service d'anatomie pathologique, CHU d'UCL Namur (site Godinne), Namur, Belgique

    3 shared publications
  • Anne Rullier

    Service de Pathologie, Place Amélie Rabat-Léon, CHU Bordeaux, Bordeaux, France

    2 shared publications
  • Brigitte Le Bail

    BRIC (BoRdeaux Institute of onCology), University of Bordeaux, Bordeaux, France

    2 shared publications
  • Béatrice Vergier

    Department of Pathology, Bordeaux University Hospital, Bordeaux, France

    2 shared publications
  • Caroline Dutriaux

    BoRdeaux Institute of onCology (BRIC), UMR 1312 INSERM University of Bordeaux, Bordeaux, France

    2 shared publications

Latest Publications

  • Transformation écologique et qualité des analyses en anatomie et cytologie pathologiques : une équation pas si insoluble

    by Rémi Vergara, Clara Mourgues, David Bailloux, Laetitia Gandino, Marie Del Castillo, Thomas Depoilly, Alexis Trecourt, Ivan Théate, Clément Tondon, Anne Rullier

  • Open Access

    Improving diagnostic accuracy in atypical melanocytic tumors using p16 immunohistochemistry and 9p21 fluorescence in situ hybridization: analysis of 206 second opinion cases

    by Rémi Vergara, Elodie Laharanne, Arnaud de la Fouchardière, Audrey Gros, Jean-Philippe Merlio, Mathilde Guyon, Caroline Dutriaux, Marie Beylot-Barry, Béatrice Vergier, Fanny Beltzung

    Diagnosing atypical melanocytic tumors can be challenging without molecular characterization, necessitating simple tools to enhance diagnostic accuracy in daily practice. This study retrospectively analyzed the utility of p16 immunohistochemistry (IHC) and 9p21 fluorescence in situ hybridization (FISH) on 206 tumors referred for expert second opinion. The performance of p16 and 9p21 was compared to histological diagnosis (both initial and final respectively without and with p16 and 9p21 status), histological subtype, and follow-up data. Negative p16 immunolabelling detected 90% of malignant cases, while only 11% of benign tumors were p16 negative. Homozygous 9p21deletion detected 42% of malignant tumors and excluded 95% of benign ones. Heterozygous deletion showed no diagnostic value. Homozygous 9p21 deletion significantly improved diagnostic confidence (P < 0.001), leading to tumor upgrading (n = 23) or melanoma confirmation (n = 22). Among 97 patients with follow-up, 17 had adverse outcomes. Kaplan–Meier analysis showed no significant difference in progression-free survival between groups (P = 0.64). Combining both techniques ultimately enhanced histological diagnostic confidence in daily practice. However, in cases where p16 is negative without homozygous deletion, or where histological malignancy is uncertain and p16 positive, other p16-inactivation mechanisms or molecular anomalies should be considered, necessitating further molecular investigations.


  • Open Access

    Recycled formalin: a new tool to mitigate the environmental impact of surgical pathology in routine practice

    by Anne Rullier, Samuel Amintas, Maxime Marques, Brigitte Le Bail, Geneviève Belleannée, Pierre Dubus, Rémi Vergara, Noelle Bernard


  • Surgical pathology and sustainable development: international landscape and prospects

    by Rémi Vergara, Ivan Théate, Peter Boor, Ilyssa O Gordon, Jonathan West, Selma Abdelmoula, Cyprien Tilmant, Roque Gabriel Wiseman Pinto, Lucie Gaillot-Durand, Sheri Scott, et al.

    The healthcare sector significantly contributes to global greenhouse gas emissions, with surgical pathology (SP) playing a notable role. This review explores the ecological transformation of SP, offering a global overview of existing challenges and sustainable initiatives worldwide. While some countries, such as the UK and France, have developed national strategies to reduce the carbon footprint of healthcare, including SP, many regions remain at an early stage of implementing green practices. Several studies have assessed the carbon footprint of SP, focusing on key aspects such as laboratory operations, pathology procedures and functional units, highlighting materials and transportation as major contributors to emissions. The integration of digital pathology and artificial intelligence (AI) presents opportunities to enhance efficiency and address medical deserts but also poses challenges due to the associated energy consumption. Local initiatives such as the ‘Transformation Ecologique en Anatomie et Cytologie Pathologiques’ (Ecological transformation in SP) or TEAP collective in France, Belgium’s ‘Green Team’ and sustainable practices in Tunisia and New Zealand demonstrate the global effort to reduce the environmental impact of SP. Key strategies discussed include ecodesign of care, circular economy practices, green AI and partnerships with industry. However, achieving meaningful reductions in SP’s environmental impact requires international cooperation and support from national health policies. This review emphasises the importance of collaborative efforts to implement sustainable solutions without compromising the quality and safety of healthcare services.


  • Open Access

    Recurrent primary cutaneous marginal zone lymphoma: a comparative study of initial tumours, recurrences, and outcomes in 61 patients

    by Fanny Beltzung, Marie Beylot‐Barry, Maxime Battistella, Caroline Ram‐Wolff, Adèle de Masson, Jean‐Michel Cayuela, Brigitte Balme, Marie Donzel, Stéphane Dalle, Florent Grange, et al.

    Aims: Primary cutaneous marginal zone lymphoma (PCMZL) is considered a lymphoproliferative disorder (International Consensus Classification, ICC) or an overt lymphoma (WHO‐HAEM5). Seeking evidence for a reactive process or true lymphoma, we retrieved recurrent PCMZLs from the French Study Group of Cutaneous Lymphoma (GFELC) database.Methods: Histology, phenotype (light‐chain restriction, immunoglobulin, and immune‐receptor translocation‐associated protein‐1 [IRTA1] expression) and B‐cell clonality at diagnosis and recurrence were compared according to recurrence site (local, locoregional, or distant) and outcomes.Results: Initial lesions of the 61 patients (mean age 52) were mostly isolated on the trunk (48%) and classified T1 (70%). Times to first recurrence for local, locoregional, and distant recurrences, were 20, 29, and 37 months, respectively. Light‐chain restriction type did not differ significantly between local/locoregional recurrences and distal recurrences (P = 0.06; n = 60). The same B‐cell clones were identified for 23/42 local/locoregional recurrences, while 5/19 distant recurrences showed different clonal profiles (P = 0.0003). No tumour expressed IRTA1. Fifty‐eight tumours were heavy‐chain (IgG/IgG4) class‐switched PCMZLs and 3 IgM+/IgD– PCMZLs. All IgM+ tumours underwent either transformation (skin or brain) into diffuse large B‐cell lymphomas (DLBCLs) and extracutaneous spreading.Conclusion: As suggested by WHO‐HAEM5, immunoglobulin phenotype assessment (IgM alongside IgD) appears to be a possible valuable tool in the initial diagnosis of PCMZL to differentiate between the indolent class‐switched PCMZL (IgM‐negative) and IgM+ (IgD–) PCMZL, which has an uncertain prognosis. The variation in B‐cell rearrangements and light chain restriction observed in distant recurrences of PCMZL may suggest different antigen‐driven stimulation processes.


  • Thymic blue melanoma arising on an extracutaneous blue naevus

    by Rémi Vergara, Paul Cirotteau, Marion Marty, Romain Hustache, Caroline Dutriaux, Fanny Beltzung, Arnaud de la Fouchardière

  • Le formol recyclé : un nouvel outil d’atténuation de l’impact environnemental de l’ACP ?

    by Matthieu Chicaud, Rémi Vergara, Ivan Théate, Perrine Lesne, Anne Rullier, pour le Teap


  • Reducing reflex first-line prescriptions in a surgical pathology laboratory: toward sustainable practice with positive economic and clinical effects

    by Rémi Vergara, Rudy Chouvel, Béatrice Vergier, Brigitte Le Bail, Marie-Laure Négrier-Leibreich, Geneviève Belleannée, Anne Rullier, Marion Marty

    In surgical pathology departments, reflex first-line techniques (RFLTs) are aimed at reducing workloads and addressing recent shortages of medical personnel. However, the impacts thereof on economic and diagnostic factors have been poorly addressed. Also, in the era of global warming, environmental considerations are crucial. This study assessed the economic and diagnostic efficacies of routine pathological RFLT and the quality of care and sustainability. Ten RFLTs of the Bordeaux University Hospital pathology department (six special stains, one cytology technique, and three immunohistochemical tests) were studied. First, a retrospective economic analysis evaluated the average cost of these RFLTs per slide and per year. Second, diagnostic relevance was prospectively surveyed. Third, the effects of changes made were analyzed over 2 years. The ten RFLTs were associated with average annual costs of €46,708. Diagnostic relevance analysis indicated that most stains were unnecessary; only 17% were requested as second-line techniques. Elimination of 7/10 tests afforded annual cost savings of €22,522 and reduced the workload by 5568 tests/year, without compromising the workflow or diagnostic quality. Seven of ten RFLTs could be eliminated without compromising diagnostic quality or the workflow. This afforded not only financial benefits but also positive social and environmental impacts. We offer valuable insights into appropriate practices in surgical pathology laboratories. Collaboration between the medical and technical teams was crucial; other healthcare sectors would also benefit from our approach.